Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
NCT ID: NCT04910295
Last Updated: 2023-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
112 participants
OBSERVATIONAL
2021-03-26
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients
NCT05062525
Vaccination Against COVID-19 in Cancer
NCT04715438
Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment
NCT05119738
Host Immune Response to Novel RNA COVID-19 Vaccination
NCT04784689
SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients
NCT05313074
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19 vaccine
Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are receiving or received anti-cancer drugs
* Those who are not vaccinated against COVID-19 at the time of enrollment
* Written informed consent
Exclusion Criteria
* Those who were already vaccinated
* Those who are on immunosuppressants or infected with HIV
* Those who underwent organ transplantation
* Active infections (for example, pneumonia)
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kyung-Hun Lee
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2013-121-1206
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.